Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 2, 2009, Pages 217-221

  Rubio Viqueira, B ^a   Hidalgo, M ^a,b  

^a Hospital Madrid Norte Sanchinarro   (Spain)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL TISSUE; CANCER CHEMOTHERAPY; CANCER REGRESSION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SCREENING; ECTOPIC TISSUE; FEMALE; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMAN XENOGRAFT; IN VIVO XENOGRAFT TUMOR MODEL; LEUKEMIA CELL; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SPECIES DIFFERENCE; TRANSGENICS; TREATMENT RESPONSE; TUMOR MODEL; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; HUMANS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58549118535     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.200     Document Type: Review

References (31)

1. DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
2. Von Hoff, D.D. There are no bad anticancer agents, only bad clinical trial designs - twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin. Cancer Res. 4, 1079-1086 (1998).
3. Venditti, J.M., Wesley, R.A. & Plowman, J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv. Pharmacol. Chemother. 20, 1-20 (1984).
4. Boyd, M. The NCI in vitro anticancer drug discovery screen: concept, implementation, and operation, 1985-1995. In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (ed. Teicher, B.) 23 (Humana, Totowa, NJ, 1997).
5. Decker, S., Hollingshead, M., Bonomi, C.A., Carter, J.P. & Sausville, E.A. The hollow fibre model in cancer drug screening: the NCI experience. Eur. J. Cancer 40, 821-826 (2004).
6. Johnson, J.I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001).
7. Hausser, H.J. & Brenner, R.E. Phenotypic instability of Saos-2 cells in long-term culture. Biochem. Biophys. Res. Commun. 333, 216-222 (2005).
8. De Wever, O. & Mareel, M. Role of tissue stroma in cancer cell invasion. J. Pathol. 200, 429-447 (2003).
9. Rubio-Viqueira, B. et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 12, 4652-4661 (2006).
10. Bankert, R.B., Egilmez, N.K. & Hess, S.D. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. 22, 386-393 (2001).
11. Perez-Soler, R. et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin. Cancer Res. 6, 4932-4938 (2000).
12. Williams, S.S. et al. Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice. J. Immunol. 156, 1908-1915 (1996).
13. Simpson-Abelson, M.R. et al. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J. Immunol. 180, 7009-7018 (2008).
14. Fichtner, I. et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur. J. Cancer 40, 298-307 (2004).
15. Fiebig, H.H., Maier, A. & Burger, A.M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 40, 802-820 (2004).
16. Eccles, S. Models for evaluation of targeted therapies of metastatic disease. In Tumor Models in Cancer Research (ed. Teicher, B.A.) 293-319 (Humana, Totowa, NJ, 2002).
17. Fidler, I.J. et al. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev. 13, 209-222 (1994).
18. Manzotti, C., Audisio, R.A. & Pratesi, G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin. Exp. Metastasis 11, 5-14 (1993).
19. Kerbel, R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2, S134-S139 (2003).
20. Wang, X., Fu, X., Brown, P.D., Crimmin, M.J. & Hoffman, R.M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 54, 4726-4728 (1994).
21. Bibby, M.C. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur. J. Cancer 40, 852-857 (2004).
22. Yoshimura, M., Endo, S., Hioki, K., Ueyama, Y. & Ohnishi, Y. Chemotherapeutic profiles of human tumors implanted in SCID mice showing appreciable inconsistencies with those in nude mice. Exp. Anim. 46, 153-156 (1997).
23. Peterson, J.K. & Houghton, P.J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40, 837-844 (2004).
24. Inaba, M. et al. Evaluation of antitumor activity in a human breast tumor/ nude mouse model with a special emphasis on treatment dose. Cancer 64, 1577-1582 (1989).
25. Tashiro, T. et al. Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother. Pharmacol. 24, 187-192 (1989).
26. Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. Nat. Rev. Cancer 2, 11-18 (2002).
27. Sausville, E.A. & Feigal, E. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA. Ann. Oncol. 10, 1287-1291 (1999).
28. Jimeno, A. et al. A prospective validation of a direct tumor xenograft model in pancreatic ductal adenocarcinoma (PDA). ASCO Annual Meeting, Chicago, IL, 2008. Abstract 4500.
29. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
30. Tan, A., Jimeno, A., Rubio-Viqueira, B. & Hidalgo, M. NCI-60 gene set connectivity map (GS-CMAP): connecting pathway-based gene expression profiles for therapeutic efficacy determination. ASCO Annual Meeting, Chicago, IL, 2008. Abstract 3588.
31. Newell, D.R., Burtles, S.S., Fox, B.W., Jodrell, D.I. & Connors, T.A. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br. J. Cancer 81, 760-768 (1999).